Literature DB >> 23356411

Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy.

Zachary L Smith1, John P Christodouleas, Stephen M Keefe, S Bruce Malkowicz, Thomas J Guzzo.   

Abstract

WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: Bladder preservation therapies for muscle-invasive bladder cancer (MIBC) have been developed to address the needs of two cohorts: patients with severe medical co-morbidities for whom radical cystectomy is too high risk and patients with limited disease who wish to avoid aggressive surgery. There are multiple bladder preservation options, although the trimodal approach of maximal transurethral resection with chemoradiotherapy is the most strongly supported. While outcomes are worse for patients unfit for surgery than those otherwise fit for surgery, bladder preservation approaches still offer curative potential. We present a comprehensive review of the literature and outline a practical approach to bladder preservation therapy for MIBC. This review aims to help urologists easily navigate through the decision tree of therapeutic options. Radical cystectomy (RC) is associated with considerable morbidity. Aside from the perioperative period, RC with urinary diversion poses great potential for long-term complications and morbidity. Bladder preservation therapies for muscle-invasive bladder cancer (MIBC) have been developed to address the needs of two cohorts: patients with severe medical co-morbidities for whom a radical surgery is too high risk and patients with limited disease who wish to avoid radical surgery. The goal of achieving complete response to treatment while maintaining bladder form and function has led to the development of multimodal approaches to this disease. There are multiple bladder preservation options, although the trimodal approach of maximal transurethral resection with chemoradiotherapy is the most strongly supported. In medically operable patients ('fit' for surgery), there is abundant evidence to support trimodal therapy as an acceptable treatment option for highly selected patients with MIBC with favourable pathological parameters. While outcomes are worse for medically inoperable patients ('unfit' for surgery), bladder preservation approaches still offer curative potential. However, prospective trials comparing the above regimens to RC are still needed to better define their role in the treatment of MIBC. We present a comprehensive review of the literature and outline a practical approach to bladder preservation therapy for MIBC.
© 2013 BJU International.

Entities:  

Mesh:

Year:  2013        PMID: 23356411     DOI: 10.1111/j.1464-410X.2012.11762.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  19 in total

1.  Impact of 2004 ISUP/WHO classification on bladder cancer grading.

Authors:  Soum D Lokeshwar; Roberto Ruiz-Cordero; Marie C Hupe; Merce Jorda; Mark S Soloway
Journal:  World J Urol       Date:  2015-04-02       Impact factor: 4.226

2.  Muscle-invasive bladder cancer treated with TURB followed by concomitant boost with small reduction of radiotherapy field with or without of chemotherapy.

Authors:  Jadwiga Nowak-Sadzikowska; Tomasz Skóra; Bogumiła Szyszka-Charewicz; Jerzy Jakubowicz
Journal:  Rep Pract Oncol Radiother       Date:  2015-09-29

3.  A Phase 1/2 Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation After Transurethral Surgery for Noncystectomy Candidates With Muscle-Invasive Bladder Cancer (Trial NRG Oncology RTOG 0524).

Authors:  M Dror Michaelson; Chen Hu; Huong T Pham; Douglas M Dahl; Chin Lee-Wu; Gregory P Swanson; Jacqueline Vuky; R Jeffrey Lee; Luis Souhami; Brian Chang; Asha George; Howard Sandler; William Shipley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-12-19       Impact factor: 7.038

4.  Cause of death of patients with non-muscular invasive, non-metastatic muscular invasive and metastatic bladder cancer after diagnosis.

Authors:  Pan Song; Ni Lu; Jiahe Zhang; Xin Gao; Xiong Li; Yaxin Li; Luchen Yang; Zhenghuan Liu; Kai Ma; Qiang Dong
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

Review 5.  The health economics of bladder cancer: an updated review of the published literature.

Authors:  Christina Yeung; Tuan Dinh; Joseph Lee
Journal:  Pharmacoeconomics       Date:  2014-11       Impact factor: 4.981

Review 6.  Landmarks in the treatment of muscle-invasive bladder cancer.

Authors:  Niyati Lobo; Chloe Mount; Kawa Omar; Rajesh Nair; Ramesh Thurairaja; Muhammad Shamim Khan
Journal:  Nat Rev Urol       Date:  2017-07-04       Impact factor: 14.432

7.  Platelet-derived growth factor receptor beta: a novel urinary biomarker for recurrence of non-muscle-invasive bladder cancer.

Authors:  Jiayu Feng; Weifeng He; Yajun Song; Ying Wang; Richard J Simpson; Xiaorong Zhang; Gaoxing Luo; Jun Wu; Chibing Huang
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240

Review 8.  STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy.

Authors:  Melanie Spitzner; Reinhard Ebner; Hendrik A Wolff; B Michael Ghadimi; Jürgen Wienands; Marian Grade
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

Review 9.  Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature.

Authors:  Vicente Guillem; Miguel Angel Climent; Javier Cassinello; Emilio Esteban; Daniel Castellano; José Luis González-Larriba; Pablo Maroto; Carlos Camps
Journal:  BMC Urol       Date:  2015-03-13       Impact factor: 2.264

Review 10.  Bladder Preservation for Muscle Invasive Bladder Cancer.

Authors:  Arafat Mirza; Ananya Choudhury
Journal:  Bladder Cancer       Date:  2016-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.